‘It’s us against the world’: And George Yan­copou­los wants you to know they are beat­ing the world — big time

George Yan­copou­los doesn’t think very high­ly of the com­pe­ti­tion Re­gen­eron $REGN faces in the fren­zied scram­ble for a ma­jor share of the PD-1/L1 mar­ket.

Dur­ing a fair­ly brief sit-down at JP­Mor­gan, the Re­gen­eron R&D chief ridiculed Pfiz­er’s choice for check­point part­ner­ing, said mar­ket leader Mer­ck was now be­ing forced to play catch-up on Re­gen­eron’s first ap­proved in­di­ca­tion for their check­point Lib­tayo (cemi­plimab) and slammed the use of PD-L1s in gen­er­al — one of two tar­gets used to re­lease an im­mune sys­tem at­tack on can­cer cells — as “med­ical mal­prac­tice.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER